Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab in Pediatric High Risk or Refractory/Relapsed Neuroblastoma
NCT06013618Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Sun Yat-sen University. Started Jun 2023; status: recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06013618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013618.